Zhitong Finance App News, Heavy Pharmaceutical Holdings (000950.SZ) announced that Chongqing Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as “Heavy Pharmaceutical Co., Ltd.”), a holding subsidiary of the company, recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration. The drug name: tofatib citrate tablets.

According to the announcement, tofatib citrate tablets are a Janus kinase (JAK) inhibitor developed by Pfizer to treat various inflammation-related immune diseases. It was first marketed in the US in 2012 and entered China in 2017. The trade name is Shang Jie/XELJANZ. The approved indications for this product are rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Heavy Pharmaceutical Co., Ltd. develops and produces drugs through the form of a drug marketing license holder (MAH), and strictly controls the quality and safety of drugs throughout the life cycle. After obtaining the registration approval for tofacib citrate tablets, they can be produced and sold domestically, further enriching the company's range of formulations, forming reasonable complementarity with the company's traditional drug distribution business, and improving the company's market competitiveness. At the same time, according to relevant national policies, the company approved the production of tofatib citrate tablets according to the 4 categories of chemicals and can pass the consistency evaluation. This will help expand the market sales of the company's products and have a positive impact on the company's future business performance.